Glenpoint Centre East 300 Frank W. Burr Blvd. Teaneck, New Jersey, 07666

201-692-9434

TRANSEPITHELIAL CXL

CLINICAL TRIAL OF TRANSEPITHELIAL CORNEAL COLLAGEN CROSSLINKING

We are pleased to announce a new clinical trial of transepithelial corneal collagen crosslinking (CXL) for keratoconus and corneal ectasia after previous refractive surgery. This study compares two variants of transepithelial crosslinking, otherwise know as “epi-on” crosslinking. All subjects will undergo pre-treatment with a topical anesthetic (to improve riboflavin absorption) and riboflavin 0.1% for 60 minutes. During UV irradiation, subjects will be randomized to receive one of two treatments - administration of riboflavin every 1 minute with UV light or administration of riboflavin every 2 minutes with UV light. The primary goal is to evaluate efficacy of the two transepithelial procedures. The second goal is to determine if there is equivalency between groups.

Transepithelial crosslinking, in which the epithelium is not removed, has been proposed to offer a number of advantages over traditional crosslinking including an increased safety profile by reducing the risk of infection as no epithelial barrier will be broken, faster visual recover, and improved patient comfort in the early postoperative healing period since re-epithelialization is not required.

For further information about the trial, call 201-883-0505 or email info@vision-institute.com.